Pre-made Etrolizumab biosimilar ( Whole mAb, anti-ITGA4_ITGB7&ITGAE_ITGB7 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-200
Anti-ITGA4_ITGB7&ITGAE_ITGB7 therapeutic antibody (Pre-made Etrolizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Etrolizumab (rhuMAb Beta7) is a biopharmaceutical drug candidate being developed for the treatment of ulcerative colitis and Crohn's disease. It is a humanized monoclonal antibody against the ��7 subunit of integrins ��4��7 and ��E��7. Etrolizumab was developed by Genentech by engineering the FIB504 antibody to include human IgGl-heavy chain and ��-light chain frameworks; it is manufactured in CHO cells.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-ITGA4_ITGB7&ITGAE_ITGB7 therapeutic antibody (Pre-made Etrolizumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Crohn's disease;Ulcerative colitis|